Go to DAY 1 DAY 3 BACK to EHDN2022
| PLENARY SESSION III: Update on Ongoing Clinical Trials; Chaired by Sarah Tabrizi and Astri Arnesen |
||
Introduction Sarah Tabrizi and Astri Arnesen |
Prilenia Michael Hayden |
UniQure Ricardo Dolmetsch |
Wave Life Sciences Danlin Xu |
PTC Therapeutics Amy-Lee Bredlau |
SOM Biotech Catherine Scart |
Triplet Therepeutics Irina Antonijevic |
Panel discussion All |
|
| SHORT COMMUNICATIONS II Chaired by Katrin Lindenberg and Anne Nørremølle |
||
Novel Bioassays to Detect Soluble and Aggregated Isoforms of the Huntingtin Protein on three Technology Platforms Christian Landles |
Saliva Biomarker Discovery in Huntington’s Disease Niels Skotte |
Plasma Extracellular Small RNAs are Early Deregulated in Huntington’s Disease and Correlate with Cognitive Symptoms Ana Gámez-Valero |
Alterations in Breathing Patterns During Speech in Early and Moderate Huntington Disease Wiebke Frank |
MSH3-Targeting Antisense Oligonucleotides Halt CAG Repeat Expansions in Huntington’s Disease IPSC-Derived Neurons Emma Bunting |
A Genome-Wide Screening in Pluripotent Cells Identifies MTF1 as a Novel Suppressor of Mutant Huntingtin Toxicity Anna Maria Gambetta |
| EHDN Business Meeting |
Anne Rosser and Patrick Weydt |
| PARALLEL SESSION II: The Use of Biomarkers in Clinical Trials of Neurodegenerative Disorders; Chaired by Maciej Figiel and Lauren Byrne |
|||
Neurofilaments as Biomarkers Across Neurodegenerative Disorders Henrik Zetterberg |
A Novel Ultrasensitive Assay to Measure Huntingtin Protein in a Polyglutamine-length-independent Manner Douglas Macdonald |
||
An Update on iMAGEmHTT — mHTT PET Tracer Development in the Clinic Aline Delva |
A Perspective of Unmet Biomarker Needs for HD Therapeutic Development Lauren Byrne |
||
| PARALLEL SESSION II: Neurodevelopment/Pediatric/Juvenile HD; Chaired by Sandrine Humbert |
|||
Axonal Growth Defects During Development Contribute to Early HD Signs Mariacristina Capizzi |
Growth and Development of the Striatum in Children and Adolescents at Risk for HD Radhia Kacher |
||
Huntington’s Disease in Kids Ferdinando Squitieri |
|||
| PARALLEL SESSION III: White Matter Changes in HD; Chaired by Åsa Petersén and Mahmoud Pouladi |
|||
Introduction Åsa Petersén |
Oligodendrocyte Dysfunction in HD Mahmoud Pouladi |
||
Early White Matter Pathology in the Fornix in HD Sanaz Gabery |
Glial-specific Transcriptomic Changes in HD Anna Williams and Sunniva Bøstrand |
||
| PARELLEL SESSION III: Multidisciplinary Care Chaired by Ruth Veenhuizen and Monica Busse |
||
Session Introduction Monica Busse Moral Deliberation and Dilemmas in Multidisciplinary Care Ruth Veenhuizen |
Moving Against Resistance: Implications for Physiotherapy and Physical Activity Una Jones |
Managing the Transition from Independence Manon van Kampen |
Nutrition Decision Making Margret Knoll |
Panel Discussion All |
|
| KEYNOTE LECTURE: Lessons Learnt from Other Neurodegenerative Disorders; Chaired by Patrick Weydt |
|
Introduction Patrick Weydt |
Protein Vaccination to Treat RAN Translation in C9ORF ALS Dieter Edbauer |
| KEYNOTE LECTURE: HD-ISS — A Primer for Use in Clinical Research; Chaired by Cristina Sampaio |
|
Introduction Cristina Sampaio |
HD-ISS Sarah Tabrizi |
| SPECIAL REPORT; Chaired by Jean-Marc Burgunder |
|
Introduction Jean-Marc Burgunder |
Towards an Understanding of the Post-treatment and Mechanistic Aspects of Tominersen Peter McColgan |
| ROUND TABLE DISCUSSION: What do Results from Clinical Trials Mean?Chaired by Jean-Marc Burgunder and Patrick Weydt |
Speakers: Henrik Zetterberg, Bernhard Landwehrmeyer, Jessica Koehli, Anne Rosser, Peter McColgan and Irina Antonijevic |